SWAP: Adding or Switching to PegIFN Improves Response in Patients With Chronic Hepatitis B on Long-Term NA Therapy

November 8-12, 2019; Boston, Massachusetts
Patients on stable nucleos(t)ide analogue therapy who added or switched to pegIFN had significantly better HBeAg loss rates and HBsAg level reductions compared with patients who continued nucleos(t)ide analogue therapy alone.
Format: Microsoft PowerPoint (.ppt)
File Size: 186 KB
Released: November 16, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

CCO commentary from Paul Y. Kwo, MD, on new HBV treatment and management data presented at AASLD 2020 Virtual

Paul Y. Kwo, MD Released: December 21, 2020

CCO expert slideset of key viral hepatitis data from AASLD 2020, including data on HBV management, identifying risk for HCC, trends in HCV treatment outcomes, and more

Norah Terrault Headshot Norah Terrault, MD, MPH Released: November 25, 2020

Norah Terrault, MD, MPH, discusses new viral hepatitis data reported at the virtual AASLD 2020 liver meeting, in the CCO Infectious Disease podcast

Norah Terrault Headshot Norah Terrault, MD, MPH Released: November 25, 2020

Dr. Stefan Zeuzem discusses new viral hepatitis data reported at the 2020 Digital International Liver Congress, in the CCO Infectious Disease podcast

Stefan Zeuzem, MD Released: September 14, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue